286 related articles for article (PubMed ID: 34889443)
21. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
22. Luspatercept: First Approval.
Markham A
Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
[TBL] [Abstract][Full Text] [Related]
23. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
Garbowski MW; Ugidos M; Risueño A; Shetty JK; Schwickart M; Hermine O; Porter JB; Thakurta A; Vodala S
Am J Hematol; 2024 Feb; 99(2):182-192. PubMed ID: 37782758
[TBL] [Abstract][Full Text] [Related]
24. Investigational drugs in phase I and phase II clinical trials for thalassemia.
Motta I; Scaramellini N; Cappellini MD
Expert Opin Investig Drugs; 2017 Jul; 26(7):793-802. PubMed ID: 28540737
[TBL] [Abstract][Full Text] [Related]
25. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
26. Real-life experience with luspatercept in transfusion-dependent β-thalassemia.
Roccotelli D; Grande D; Cicco G; Palma A; Longo MC; Albano F; Vitucci A; Musto P
Ann Hematol; 2023 Oct; 102(10):2965-2967. PubMed ID: 37498329
[No Abstract] [Full Text] [Related]
27. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
[TBL] [Abstract][Full Text] [Related]
28. Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).
Alashkar F; Klump H; Lange CP; Proske P; Schüssler M; Yamamoto R; Carpinteiro A; Berliner CA; Schlosser TW; Röth A; Reinhardt HC
Eur J Haematol; 2022 Dec; 109(6):664-671. PubMed ID: 36045599
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
[TBL] [Abstract][Full Text] [Related]
30. Drug safety in thalassemia: lessons from the present and directions for the future.
Grech L; Sultana J; Borg K; Borg J
Expert Opin Drug Saf; 2021 Aug; 20(8):937-947. PubMed ID: 33877003
[No Abstract] [Full Text] [Related]
31. Novel Therapeutic Advances in β-Thalassemia.
Makis A; Voskaridou E; Papassotiriou I; Hatzimichael E
Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34207028
[TBL] [Abstract][Full Text] [Related]
32. Ineffective erythropoiesis and its treatment.
Cazzola M
Blood; 2022 Apr; 139(16):2460-2470. PubMed ID: 34932791
[TBL] [Abstract][Full Text] [Related]
33. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
[TBL] [Abstract][Full Text] [Related]
34. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
35. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
36. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.
Thuret I; Ruggeri A; Angelucci E; Chabannon C
Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028
[TBL] [Abstract][Full Text] [Related]
37. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
38. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
39. Activin receptor ligand traps in chronic kidney disease.
Jelkmann W
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
[TBL] [Abstract][Full Text] [Related]
40. An Expert Overview on Therapies in Non-Transfusion-Dependent Thalassemia: Classical to Cutting Edge in Treatment.
Saeidnia M; Fazeli P; Farzi A; Atefy Nezhad M; Shabani-Borujeni M; Erfani M; Tamaddon G; Karimi M
Hemoglobin; 2023 Nov; 47(2):56-70. PubMed ID: 37325871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
